Melphalan HCl 50mg/vial; pwd for IV infusion after reconstitution and dilution. Melphalan is an alkylating agent with cytotoxic action that appears to be related to the extent of its interstrand ...

Serious adverse events occurred in 51.2 and 21.9% of patients receiving melphalan/hepatic delivery system and BAC, respectively. HealthDay News — For patients with unresectable metastatic uveal ...

Oral melphalan and dexamethasone (MDex ... BMDex was observed in patients without severe (New York Heart Association class III or IV) heart failure and with N-terminal pro-natriuretic peptide ...

The established conventional therapy is treatment with melphalan and prednisone. We investigated whether treatment with multiple alkylating agents improved the response rate or survival time, compared ...

Discover comprehensive details about Melphalan, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the immediate availability in the United States of Melphalan Hydrochloride for Injection. Fresenius Kabi Melphalan Hydrochloride ...

Consolidation therapy with high-dose melphalan plus stem-cell transplantation, as compared with MPR, significantly prolonged progression-free and overall survival among patients with multiple ...

The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone. This phase 3 study compared the use of melphalan and prednisone ...

Spectrum Pharmaceuticals is taking over the effort to develop and commercialize Ligand Pharmaceuticals’ Captisol®-enabled, propylene glycol-free (PG-free) melphalan as part of a potentially $53 ...

Get Instant Summarized Text (Gist) A new drug delivery system using melphalan hepatic perfusion shows promise for patients with metastatic uveal melanoma, a rare eye cancer that spreads to the ...

HealthDay News — For patients with unresectable metastatic uveal melanoma (mUM), the drug/device combination melphalan/hepatic delivery system (HDS) is efficacious and has a favorable risk-benefit ...